Take into consideration alternant therapies that are not moderate CYP3A inducers throughout therapy with mitapivat. If unable to stay clear of coadministration, observe Hb and titrate past fifty mg BID, if necessary, but do not exceed mitapivat dose of a hundred mg BID. .pentobarbital will lessen the level or outcome of bortezomib by impacting hepa